| Number of patients | 139 |
| Age (years), mean (±SD) | 61,8 (±7,0) |
| cT3a | 89,9% () | cT3b | 10,1% () | Biopsy Gleason score, median (range) | 7 (2–10) | PSA (ng/mL), mean (range) | 13,73 (3,1–97,0) |
| Previous surgery | 14,4% () | Neo-Adjuvant Androgen Deprivation Therapy | 8,6% () | Non-nerve-sparing procedure | 92,8% () |
| Unilateral nerve sparing procedure | 7,2% () | Lymphadenectomy not performed | 7,2% () | Hospital stay (days), median (range) | 12 (5–27) |
| pT2 | 31,1% () | pT3a | 51,1% () | pT3b | 16,3% () | pT4 | 1,5% () |
| PSA persistence | 10,1% () | Pathological Gleason score, median (range) | 7 (4–9) | Pathological node positive | 10,1% () | Surgical margin positive | 13,7% () |
| Adj radiation therapy within 1 year | 7,2% () | Adj endocrine therapy within 1 year | 13,7% () |
|
|